Mesenchymal stem cells (MSCs) have been isolated from bone marrow, periosteum,
trabecular bone, adipose tissue, synovium, skeletal muscle and deciduous teeth. These …

Emerging evidence suggests that bone marrow–derived endothelial, hematopoietic stem
and progenitor cells contribute to tissue vascularization during both embryonic and postnatal …

Background—The delivery of autologous cells to increase angiogenesis is emerging as a
treatment option for patients with cardiovascular disease but may be limited by the …

We recently demonstrated that marrow stromal cells (MSCs) augment collateral remodeling
through release of several cytokines such as VEGF and bFGF rather than via cell …

Background—Bone marrow cell therapy is reported to contribute to collateral formation
through cell incorporation into new or remodeling vessels. However, the possible role of a …

Background—Experimental studies suggest that transplantation of blood-derived or bone
marrow–derived progenitor cells beneficially affects postinfarction remodeling. The safety …

Mesenchymal stem cells (MSCs) represent a stem cell population present in adult tissues
that can be isolated, expanded in culture, and characterized in vitro and in vivo. MSCs …

Background Previous studies have shown improvement in left ventricular function after
intracoronary injection of autologous cells derived from bone marrow (BMC) in the acute …

Background—This study evaluated the hypothesis that transendocardial injections of
autologous mononuclear bone marrow cells in patients with end-stage ischemic heart …

Background—Bone marrow–derived stem cells are under investigation as a treatment for
ischemic heart disease. Mesenchymal stem cells (MSCs) have been used preferentially in …